AU2001255179A1 - Therapy of proliferative disorders by direct irradiation of cell nuclei with tritiated nuclear targeting agents - Google Patents

Therapy of proliferative disorders by direct irradiation of cell nuclei with tritiated nuclear targeting agents

Info

Publication number
AU2001255179A1
AU2001255179A1 AU2001255179A AU5517901A AU2001255179A1 AU 2001255179 A1 AU2001255179 A1 AU 2001255179A1 AU 2001255179 A AU2001255179 A AU 2001255179A AU 5517901 A AU5517901 A AU 5517901A AU 2001255179 A1 AU2001255179 A1 AU 2001255179A1
Authority
AU
Australia
Prior art keywords
therapy
proliferative disorders
cell nuclei
targeting agents
direct irradiation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001255179A
Inventor
Robert A. Gatenby
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Temple University of Commonwealth System of Higher Education
Original Assignee
Temple University of Commonwealth System of Higher Education
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Temple University of Commonwealth System of Higher Education filed Critical Temple University of Commonwealth System of Higher Education
Publication of AU2001255179A1 publication Critical patent/AU2001255179A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0491—Sugars, nucleosides, nucleotides, oligonucleotides, nucleic acids, e.g. DNA, RNA, nucleic acid aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0493—Steroids, e.g. cholesterol, testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1217—Dispersions, suspensions, colloids, emulsions, e.g. perfluorinated emulsion, sols
    • A61K51/1234—Liposomes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Optics & Photonics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dispersion Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2001255179A 2000-03-24 2001-03-16 Therapy of proliferative disorders by direct irradiation of cell nuclei with tritiated nuclear targeting agents Abandoned AU2001255179A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US19215300P 2000-03-24 2000-03-24
US60/192,153 2000-03-24
US19267100P 2000-03-28 2000-03-28
US60/192,671 2000-03-28
PCT/US2001/008446 WO2001072203A2 (en) 2000-03-24 2001-03-16 Therapy of proliferative disorders by direct irradiation of cell nuclei with tritiated nuclear targeting agents

Publications (1)

Publication Number Publication Date
AU2001255179A1 true AU2001255179A1 (en) 2001-10-08

Family

ID=26887786

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001255179A Abandoned AU2001255179A1 (en) 2000-03-24 2001-03-16 Therapy of proliferative disorders by direct irradiation of cell nuclei with tritiated nuclear targeting agents

Country Status (3)

Country Link
EP (1) EP1283674A4 (en)
AU (1) AU2001255179A1 (en)
WO (1) WO2001072203A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
JP2019513709A (en) 2016-04-01 2019-05-30 セラピューティックスエムディー インコーポレーテッドＴｈｅｒａｐｅｕｔｉｃｓｍｄ， Ｉｎｃ． Steroid hormone pharmaceutical composition
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE914220A1 (en) * 1990-12-10 1992-06-17 Akzo Nv Labelled, modified oligonucleotides
DE69429087T2 (en) * 1993-01-07 2002-07-11 Thomas Jefferson University Ph MODULATION OF PROLIFERATION OF SMOOTH MUSCLE CELLS BY ANTISENSE INHIBITION OF C-MYC
US5847104A (en) * 1995-05-22 1998-12-08 Hybridon, Inc. Method of tritium labeling oligonucleotide
US5821354A (en) * 1996-11-26 1998-10-13 Angiogene Inc. Radiolabeled DNA oligonucleotide and method of preparation

Also Published As

Publication number Publication date
WO2001072203A3 (en) 2002-10-10
WO2001072203A2 (en) 2001-10-04
EP1283674A4 (en) 2005-04-27
EP1283674A2 (en) 2003-02-19

Similar Documents

Publication Publication Date Title
US5484778C1 (en) Phthalocynine photosensitizers for photodynamic therapy and methods for their use
AU7380500A (en) Methods for treating tumors using neutron therapy
AU2001249549A1 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
IL152531A0 (en) Tropane derivatives useful in therapy
GB2361399B (en) System and method for optimizing radiation treatment with an intensity modulating multi-leaf collimator
AU2210400A (en) Method of using a cyclooxygenase-2 inhibitor and an integrin antagonist as a combination therapy in the treatment of neoplasia
AU7994200A (en) Compositions and methods for therapy and diagnosis of prostate cancer
EP1690323A4 (en) Method of modulating laser-accelerated protons for radiation therapy
GB2370745B (en) High definition conformal arc radiation therapy with muti-leaf collimator
EP1146912A4 (en) Method for improved radiation therapy
HUP0200441A2 (en) Tetrahydropyran derivatives and their use as therapeutic agents and process for preparation the compounds
PT1702618E (en) Use of et743 in combination therapy with dexamethasone for treating cancer
AU1264200A (en) Use of neoangiogenesis markers for diagnosing and treating tumours by therapy
PL363478A1 (en) Conjugates of immune cell specific macrolide compounds with anti-inflammatory compounds for improved cellular targeting of anti-inflammatory therapy
AU2001287890A1 (en) Radiotherapy apparatus and collimator set therefor
NO20016146L (en) Apparatus for therapy with electrical potential
AU2002302010A1 (en) Device for Effecting Radiation Therapy in an Animal Body
EP1263449A4 (en) Induction of beta cell differentiation in human cells by stimulation of the glp-1 receptor
AU3086900A (en) Device for the complex treatment of disorders of the prostate
DE60039247D1 (en) SPIRO (2H-1-BENZOPYRANO-2,4'-PIPERIDINE) DERIVATIVES AS GLYCINTRANSPORTHERMMER
GB2370961B (en) System and method for optimizing radiation treatment with an intensity modulating multi-leaf collimator
AU2002336637A1 (en) Chlorin photosensitizing agents for use in photodynamic therapy
AU2001286398A1 (en) Apparatus for determining the position of radioactive seeds in needles used for radioactive seed therapy for prostate cancer
AU2001255179A1 (en) Therapy of proliferative disorders by direct irradiation of cell nuclei with tritiated nuclear targeting agents
ID26831A (en) POWER SUPPLY TRANSVERS